ODM-212 5 mg coated tablet
Sponsors
Orion Corporation
Conditions
Neoplasms benign malignant and unspecified (incl cysts and polyps). MedDRA [C04]Neoplasms benign malignant and unspecified (incl. cysts and polyps)
Phase 1
A phase 1/2, first-in-human study on ODM-212 in subjects with selected advanced solid tumours
RecruitingCTIS2022-503061-29-00
Start: 2024-01-22Target: 181Updated: 2025-12-17
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
Not yet recruitingCTIS2025-524620-22-00
Target: 13Updated: 2026-05-22